<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146179">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755286</url>
  </required_header>
  <id_info>
    <org_study_id>201-201101</org_study_id>
    <nct_id>NCT01755286</nct_id>
  </id_info>
  <brief_title>OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo- and Sham-Controlled, Multicenter, Phase 1b Study of OTO-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the safety and tolerability of two dose levels of
      OTO-201, placebo and sham when administered intra-operatively in pediatric subjects with
      bilateral middle ear effusion who require tympanostomy tube placement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of adverse events, otoscopic exams, audiometry, and tympanometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Activity</measure>
    <time_frame>Up to 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of physician reported and caregiver reported otorrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Eradication</measure>
    <time_frame>Up to 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Microbiological eradication of pretherapy bacteria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement</condition>
  <arm_group>
    <arm_group_label>4 mg OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 mg OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle for OTO-201</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTO-201</intervention_name>
    <description>Single intra-operative injection</description>
    <arm_group_label>4 mg OTO-201</arm_group_label>
    <arm_group_label>12 mg OTO-201</arm_group_label>
    <other_name>ciprofloxacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intratympanic injection</description>
    <arm_group_label>Vehicle for OTO-201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Simulated single intratympanic injection</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria includes, but is not limited to:

          -  Subject is a male or female aged 6 months to 12 years, inclusive

          -  Subject has a clinical diagnosis of bilateral middle ear effusion requiring
             tympanostomy tube placement

          -  Subject's caregiver is willing to comply with the protocol and attend all study
             visits

        Exclusion Criteria includes, but is not limited to:

          -  Subject has a history of prior ear or mastoid surgery, not including myringotomy or
             myringotomy with tympanostomy tube placement

          -  Subject has a history of sensorineural hearing loss

          -  Subject has a history of chronic or recurrent bacterial infections other than otitis
             media that likely will require treatment with antibiotics during the course of the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl LeBel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Otonomy, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Call/Email Otonomy Central Contact for Trial Locations</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 17, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis Media with Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
